文献速递消化系统肿瘤

TRIPLETE研究最终结果:mFOLFOXIRI联合帕尼单抗一线治疗RAS/BRAF野生型转移性结直肠癌

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
PubMed 文献 · J Clin Oncol · 2026-01-08

报告III期随机TRIPLETE研究的5年结果,RAS/BRAF野生型转移性结直肠癌患者一线接受mFOLFOX/帕尼单抗(对照组217例)或mFOLFOXIRI/帕尼单抗(试验组218例)。

要点

  • 一线mFOLFOXIRI联合帕尼单抗较mFOLFOX联合帕尼单抗显著改善RAS/BRAF野生型mCRC总生存
  • 总生存获益在各临床特征亚组中一致
  • 客观缓解率、早期肿瘤退缩、缓解深度、无残留肿瘤切除率及无进展生存均无差异

核心结论

  • 在RAS/BRAF野生型转移性结直肠癌患者中,一线mFOLFOXIRI联合帕尼单抗较mFOLFOX联合帕尼单抗显著改善总生存。

研究设计与样本

  • III期随机TRIPLETE研究5年结果,对照组mFOLFOX/帕尼单抗217例,试验组mFOLFOXIRI/帕尼单抗218例,按意向治疗人群分析。
  • 中位随访60.2个月(IQR 49.3-70.0)。

主要发现

  • 总生存获益在各临床特征中均倾向于试验组。

关键数值与推荐

  • 二线治疗比例对照组73%、试验组71%;三线51%/49%;四线31%/32%。
  • 非姑息性局部区域治疗比例两组均为16%。

临床怎么用

  • 对RAS/BRAF野生型mCRC,可考虑一线mFOLFOXIRI联合帕尼单抗以改善总生存,需权衡强化化疗的毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). We present overall survival (OS) and updated outcomes in the intention-to-treat population. The median follow-up was 60.2 months (IQR, 49.3-70.0). The median OS was 41.1 and 33.3 months for experimental and control groups, respectively (hazard ratio [HR], 0.79 [95% CI, 0.63 to 0.99]; P = .049). OS outcomes favored the experimental group regardless of clinical features. No differences in objective response rate (primary end point; 75%/78%, odds ratio, 0.84 [95% CI, 0.54 to 1.31]; P = .442), early tumor shrinkage rate (P = .954), depth of response (P = .573), no residual tumor resection rate (P = .329), and progression-free survival (HR, 0.95 [95% CI, 0.78 to 1.16]; P = .606) were confirmed. Among patients alive at the time of disease progression, the median postprogression survival was 24.6 and 17.7 months for experimental and control groups, respectively (HR, 0.79 [95% CI, 0.62 to 1.01]; P = .062). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Conca V, Rossini D, Antoniotti C, et al. Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. J Clin Oncol. 2026. PMID: 41505697. doi:10.1200/JCO-25-01337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。